https://profusa.com/injectable-body-sensors-take-personal-chemistry-to-a-cell-phone-closer-to-reality/
Injectable Body Sensors Take Personal Chemistry to a Cell Phone Closer to Reality
>https://profusa.com/injectable-body-sensors-take-personal-chemistry-to-a-cell-phone-closer-to-reality/
The research is based upon work supported by DARPA, the Biological Technologies Office (BTO), and ARO grant [W911NF-16-1-0341]. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of DARPA, BTO, the ARO, or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright annotation thereon.
Research reported in this press release is supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number R01 EB016414. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
>The research is based upon work supported by DARPA, the Biological Technologies Office (BTO), and ARO grant [W911NF-16-1-0341].
https://profusa.com/profusa-inc-awarded-7-5m-darpa-grant/
Profusa, Inc. Awarded $7.5M DARPA Grant to Develop Tissue-integrated Biosensors for Continuous Monitoring of Multiple Body Chemistries
July 12, 2016
SOUTH SAN FRANCISCO, Calif., July 12, 2016 — Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that it was awarded a $7.5 million dollar grant from the Defense Advanced Research Projects Agency (DARPA) and the U.S. Army Research Office (ARO) to develop implantable biosensors for the simultaneous, continuous monitoring of multiple body chemistries. Aimed at providing real-time monitoring of a combat soldier’s health status to improve mission efficiency, the award supports further development of the company’s biosensor technology for real-time detection of the body’s chemical constituents. DARPA and ARO are agencies of the U.S. Department of Defense focused on the developing emerging technologies for use by the military.
“Profusa’s vision is to replace a point-in-time chemistry panel that measures multiple bioÂmarkers, such as oxygen, glucose, lactate, urea, and ions with a biosensor that provides a continuous stream of wireless data,” said Ben Hwang, Ph.D., Profusa’s chairman and chief executive officer. “DARPA’s mission is to make pivotal investments in breakthrough techÂnologies for national security. We are gratified to be awarded this grant to accelerate the development of our novel tissue-integrating sensors for application to soldier health and peak performance.”
>“Profusa’s vision is to replace a point-in-time chemistry panel that measures multiple bioÂmarkers, such as oxygen, glucose, lactate, urea, and ions with a biosensor that provides a continuous stream of wireless data,” said Ben Hwang, Ph.D., Profusa’s chairman and chief executive officer. “DARPA’s mission is to make pivotal investments in breakthrough techÂnologies for national security. We are gratified to be awarded this grant to accelerate the development of our novel tissue-integrating sensors for application to soldier health and peak performance.”
https://pubmed.ncbi.nlm.nih.gov/31709808/
Near-Infrared Optical Nanosensors for Continuous Detection of Glucose
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Natalie Wisniewski and Soya Gamsey are full-time employees of Profusa, Inc.
>it is really quite weird
https://www.reuters.com/article/uk-britain-royals-meghan/duchess-meghan-speaks-about-miscarriage-in-break-with-royal-reserve-idUSKBN28510A
Britain's Duchess Meghan speaks about miscarriage in break with royal reserve